


**REMARKS**


It is noted in the Office Communication that the elected compound of component (a) does not fall within Formula (I) as defined in claim 1 as amended in Applicant's response of September 13, 2010 (Enclosed herein as Appendix B). The Examiner suggests that the elected compound requires that  $Z = CR_6R'$ ;  $R_6 = H$ ; and  $R' = n\text{-butyl-OH}$  but formula (I) does not provide for a substituted  $C_{1-6}$  alkyl in the  $R'$  position. Applicant respectfully disagrees with the Examiner's reasoning.

First, Applicant brings the Examiner's attention to the response to restriction requirement of October 26, 2009 (enclosed herein as Appendix A), wherein Applicant elected compound **1-isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one** as a specie of component (a) and Formula (I). This elected compound is represented by the following structure:



1-isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one

Second, Applicant notes that as depicted above, this compound is covered by the general compound of Formula (I) recited in currently amended claim 1 (See page 2 of Appendix B). Formula (I) covers the above compound when  $R_1$ ,  $R_2$  and  $R_3$  are H; X is a direct bond; Y is H; Z



is  $CR_6R'$ ;  $R_6$  is  $C_{1-6}$  alkyl (i.e. butyl);  $R'$  is H; and Q is  $B=B-B$  wherein A is C or N, optionally substituted with H, halogen,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, cyano- $C_{1-6}$  alkyl,  $CO_2R_4$ , aryl, benzoaminocarbonyl, hydroxybenzyl,  $SO_2NR_4R_5$  or  $C_{3-6}$  cycloalkyl. Where A is carbon, it may also be optionally substituted by O or S via a double bond;

B is C or N; where B is C it may be optionally substituted by H, C<sub>1-6</sub> alkyl, NO<sub>2</sub>, CN, halogen, COR<sub>4</sub>, COOR<sub>4</sub>, CONHR<sub>4</sub>C(=NH)NH<sub>2</sub> or C(=N<sup>+</sup>OH)NH<sub>2</sub>.

As such, Applicant submits that (1) **1-isopropenyl-3-(1-propyl-1H-benzoimidazol-2-ylmethyl)-1,3-dihydro-imidazo[4,5-c]pyridine-2-one** does not require that R' be n-butyl-OH, rather it requires R' to be propyl and (2) said compound falls within the scope of Formula (I). Applicant therefore submits that the response as presented in Appendix B is complete.

### Conclusion

In view of the above arguments, Applicant respectfully request reconsideration of amendment and response filed September 13, 2010.

It is Applicant's understanding that no fees are due with the filing of this response. However, should any additional fees be necessary, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-4876, under Order No. 117750-01801.

If a telephone conversation with Applicant's attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call the undersigned attorney at (617) 449-6500.

Dated: September 29, 2011

Respectfully submitted,

By Jermaine Lawrence/  
Jermaine A. Lawrence, Esq.  
Registration No.:68,403  
McCarter & English, LLP  
265 Franklin Street, 14<sup>th</sup> Floor  
Boston, Massachusetts 02110  
(617) 449-6500  
Fax (617) 607-9200  
Attorney/Agent For Applicant